Raymond James Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $140
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsInitiationPrice Target
Raymond James analyst Thomas Deal initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announces Price Target of $140.
Raymond James analyst Thomas Deal initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announces Price Target of $140.